British journal of clinical pharmacology

Br J Clin Pharmacol · ISSN (e) 1365-2125 · 24 papers in corpus
other 2026
doi:10.1002/bcp.70421 ·PMID:41572514

AIMS: Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescr…

other 2022
doi:10.1111/bcp.15014 ·PMID:34327754

AIMS: We report population pharmacokinetic (popPK) and exposure-response (E-R) analyses for efficacy (induced amenorrhoea [IA]) and safety (unbound oestradiol [E2] concentrations) of the selective progesterone receptor modulator vilaprisan.…

rct 2022
doi:10.1111/bcp.15358 ·PMID:35437837

AIMS: Neuronal hypersensitisation due to adenosine triphosphate-dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first-in-human study of eliapixant (BAY 1817080…

other 2022
doi:10.1111/bcp.15440 ·PMID:35695781

AIM: Elagolix, a gonadotropin-releasing hormone receptor antagonist, was recently approved for heavy menstrual bleeding associated with uterine fibroids (UF, Oriahnn) at a dose of 300 mg twice daily (BID) in combination with add-back therap…

other 2021
doi:10.1111/bcp.15171 ·PMID:34904270

AIMS: To identify linzagolix doses, an oral GnRH receptor antagonist, that effectively lower oestradiol (E2) to relieve endometriosis-related pelvic pain without compromising bone health. METHODS: Integrated statistical, pharmacokinetic-ph…

observational 2019
doi:10.1111/bcp.14027 ·PMID:31218710

AIMS: In 2017, concerns regarding adverse events (AEs) associated with the Mirena levonorgestrel intrauterine device were largely echoed in the media in France. This resulted in a tremendous reporting of AEs to pharmacovigilance centres. Th…

nonrandomized-trial 2019
doi:10.1111/bcp.13992 ·PMID:31112623

AIMS: The study objective was to evaluate the pharmacokinetics of the selective progesterone receptor modulator vilaprisan in participants with hepatic impairment. Additionally, the safety and tolerability of vilaprisan were investigated. …

review 2019
doi:10.1111/bcp.13881 ·PMID:30690761

Mathematical modelling and simulation (M&S) of drug concentrations, pharmacologic effects and the (patho)physiologic systems within which they interact can be powerful tools for the preclinical, translational and clinical development of dru…

observational 2018
doi:10.1111/bcp.13542 ·PMID:29424001

AIMS: Data available on the fetal safety of trimethoprim-sulfamethoxazole (TMP-SMX) exposure during pregnancy remains scarce and inconclusive. A previous study assessing the link between TMP-SMX exposure during pregnancy and the risk of spo…

observational 2017
doi:10.1111/bcp.13364 ·PMID:28722171

AIMS: Few studies have investigated the link between individual antibiotics and major congenital malformations (MCMs) including specific malformations owing to small sample size. We aimed to quantify the association between exposure to gest…

review 2016
doi:10.1111/bcp.13020 ·PMID:27220803

Palmitoylethanolamide (PEA) has been suggested to have useful analgesic properties and to be devoid of unwanted effects. Here, we have examined critically this contention, and discussed available data concerning the pharmacokinetics of PEA …

meta-analysis 2015
doi:10.1111/bcp.12519 ·PMID:25251944

AIMS: The objective of this review was to collect available data on the following: (i) adverse effects observed in humans from the intake of plant food supplements or botanical preparations; (ii) the misidentification of poisonous plants; a…

review 2015
doi:10.1111/bcp.12406 ·PMID:24750505

The development of biological agents with specific immunological targets has revolutionized the treatment of a wide variety of paediatric diseases where traditional immunosuppressive agents have been partly ineffective or intolerable. The i…

review 2013
doi:10.1111/j.1365-2125.2012.04350.x ·PMID:22670731

OBJECTIVES: The aim of this overview of systematic reviews (SRs) is to evaluate critically the evidence regarding interactions between herbal medicinal products (HMPs) and synthetic drugs. METHODS: Four electronic databases were searched t…

meta-analysis 2013
doi:10.1111/j.1365-2125.2012.04290.x ·PMID:22471948

AIM: Animal and in vitro studies suggest that the use of non-steroidal anti-inflammatory drugs (NSAIDs) may be associated with reduced risk for ovarian cancer. However, results from these studies have been inconsistent. The aim of our study…

case-report 2011
doi:10.1111/j.1365-2125.2011.03901.x ·PMID:21223355
lab-animal 2010
doi:10.1111/j.1365-2125.2010.03730.x ·PMID:20840449

AIMS: Early studies on gonadotrophin-releasing hormone (GnRH) antagonists pointed out histamine-mediated anaphylactic reactions as a potential adverse effect of these drug candidates. In this study we have compared the histamine-releasing p…

rct 2009
doi:10.1111/j.1365-2125.2009.03460.x ·PMID:19740402

AIMS: Within the framework of the clinical development of BX471, this study was intended to provide experience in conducting 'thorough QT(c) studies' according to ICH E14. A broad range of QT correction methods and analysis strategies was e…

nonrandomized-trial 1997
doi:10.1046/j.1365-2125.1997.t01-1-00592.x ·PMID:9354307

AIMS: Triptorelin is a gonadotropin-releasing hormone (GnRH) analogue with enhanced affinity for GnRH receptors and a prolonged half-life due to its resistance to enzymatic degradation. The sustained-release formulation of this molecule is …

1994
1994
nonrandomized-trial 1983
doi:10.1111/j.1365-2125.1983.tb02289.x ·PMID:6138071

A double-blind study was conducted in 60 female patients with moderate or severe insomnia, hospitalized for gynaecological surgery. After an initial 2-day placebo selection phase, 30 subjects received 15 mg midazolam and the remaining 30 re…

other 1981
doi:10.1111/j.1365-2125.1981.tb00538.x ·PMID:7194101
rct 1979
doi:10.1111/j.1365-2125.1979.tb04728.x ·PMID:508518